Search Results - "Rodríguez, Claudia Cárcamo"

  • Showing 1 - 11 results of 11
Refine Results
  1. 1

    Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical–radiological features and treatment. Case report of seven patients by Ciampi, Ethel, Uribe-San-Martín, Reinaldo, Godoy-Santín, Jaime, Cruz, Juan Pablo, Cárcamo-Rodríguez, Claudia, Juri, Carlos

    Published in Multiple sclerosis (01-11-2017)
    “…Secondary paroxysmal dyskinesias (SPDs) are short, episodic, and recurrent movement disorders, classically related to multiple sclerosis (MS). Carbamazepine is…”
    Get full text
    Journal Article
  2. 2

    Prevalence of epilepsy in a cohort of patients with multiple sclerosis by Uribe-San-Martín, Reinaldo, Ciampi-Díaz, Ethel, Suarez-Hernández, Felipe, Vásquez-Torres, Macarena, Godoy-Fernández, Jaime, Cárcamo-Rodríguez, Claudia

    Published in Seizure (London, England) (01-01-2014)
    “…Abstract Introduction Epilepsy prevalence is 0.27–1.7% in general population. However, higher figures have been reported in Multiple Sclerosis (MS) patients,…”
    Get full text
    Journal Article
  3. 3

    Social cognition: Concepts, neural basis and its role in multiple sclerosis by Labbé, Tomás, Ciampi, Ethel, Carcamo Rodríguez, Claudia

    Published in Neurology and clinical neuroscience (01-01-2018)
    “…Social cognition, including social perception, empathy and theory of mind, focuses on how people process, store, and apply information about other people and…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

    Use of Fingolimod in the Management of Relapsing–Remitting Multiple Sclerosis: Experience from Latin America by Correale, Jorge, Flores, Jose, Bonitto, Juan Garcia, Rodríguez, Claudia Cárcamo, Oliveira, Enedina M. L.

    Published in Advances in therapy (01-07-2015)
    “…Once-daily fingolimod 0.5 mg (FTY720; Gilenya ® , Novartis Pharma AG, Basel, Switzerland) is a sphingosine 1-phosphate receptor modulator that is approved for…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11